Towa Pharmaceutical Co., Ltd. (TYO:4553)
Japan
· Delayed Price · Currency is JPY 4,200.00
+50.00 (1.20%)
At close: Mar 6, 2026
Towa Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 269,922 | 259,594 | 227,934 | 208,859 | 165,615 | 154,900 | Upgrade
|
| Revenue Growth (YoY) | 6.54% | 13.89% | 9.13% | 26.11% | 6.92% | 40.33% | Upgrade
|
| Cost of Revenue | 170,816 | 164,865 | 146,551 | 136,145 | 95,429 | 89,448 | Upgrade
|
| Gross Profit | 99,106 | 94,729 | 81,383 | 72,714 | 70,186 | 65,452 | Upgrade
|
| Selling, General & Admin | 58,451 | 54,954 | 50,405 | 51,825 | 39,381 | 34,842 | Upgrade
|
| Research & Development | 16,212 | 16,212 | 13,242 | 15,265 | 11,488 | 10,642 | Upgrade
|
| Operating Expenses | 74,983 | 71,486 | 63,735 | 67,199 | 51,648 | 45,523 | Upgrade
|
| Operating Income | 24,123 | 23,243 | 17,648 | 5,515 | 18,538 | 19,929 | Upgrade
|
| Interest Expense | -2,146 | -1,627 | -947 | -635 | -230 | -190 | Upgrade
|
| Interest & Investment Income | 291 | 232 | 106 | 25 | 14 | 29 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,119 | 1,992 | 1,593 | 1,181 | 795 | 770 | Upgrade
|
| Other Non Operating Income (Expenses) | 3,738 | 1,051 | 527 | 905 | 725 | 527 | Upgrade
|
| EBT Excluding Unusual Items | 27,125 | 24,891 | 18,927 | 6,991 | 19,842 | 21,065 | Upgrade
|
| Gain (Loss) on Sale of Investments | -11 | -38 | -222 | -20 | -563 | -45 | Upgrade
|
| Gain (Loss) on Sale of Assets | 77 | 230 | 225 | -46 | 96 | 97 | Upgrade
|
| Asset Writedown | 1,258 | 1,247 | 5,550 | -2,282 | 2,896 | -2,388 | Upgrade
|
| Other Unusual Items | -1 | -1 | -21 | -38 | -26 | -1 | Upgrade
|
| Pretax Income | 28,448 | 26,329 | 24,459 | 4,605 | 22,245 | 18,728 | Upgrade
|
| Income Tax Expense | 7,004 | 7,343 | 8,286 | 2,404 | 6,331 | 4,770 | Upgrade
|
| Net Income | 21,444 | 18,986 | 16,173 | 2,201 | 15,914 | 13,958 | Upgrade
|
| Net Income to Common | 21,444 | 18,986 | 16,173 | 2,201 | 15,914 | 13,958 | Upgrade
|
| Net Income Growth | 11.23% | 17.39% | 634.80% | -86.17% | 14.01% | -3.76% | Upgrade
|
| Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | 49 | Upgrade
|
| Shares Outstanding (Diluted) | 49 | 49 | 49 | 49 | 50 | 51 | Upgrade
|
| Shares Change (YoY) | 0.01% | 0.01% | -0.00% | -2.19% | -1.86% | -3.57% | Upgrade
|
| EPS (Basic) | 435.61 | 385.70 | 328.58 | 44.72 | 323.35 | 283.62 | Upgrade
|
| EPS (Diluted) | 435.61 | 385.70 | 328.58 | 44.72 | 316.19 | 271.93 | Upgrade
|
| EPS Growth | 11.22% | 17.38% | 634.82% | -85.86% | 16.28% | -0.25% | Upgrade
|
| Free Cash Flow | 6,338 | -5,335 | -29,639 | -26,187 | 10,989 | 2,871 | Upgrade
|
| Free Cash Flow Per Share | 128.75 | -108.38 | -602.17 | -532.02 | 218.36 | 55.99 | Upgrade
|
| Dividend Per Share | 80.000 | 70.000 | 60.000 | 60.000 | 57.000 | 44.000 | Upgrade
|
| Dividend Growth | 33.33% | 16.67% | - | 5.26% | 29.54% | - | Upgrade
|
| Gross Margin | - | 36.49% | 35.70% | 34.82% | 42.38% | 42.25% | Upgrade
|
| Operating Margin | 8.94% | 8.95% | 7.74% | 2.64% | 11.19% | 12.87% | Upgrade
|
| Profit Margin | 7.95% | 7.31% | 7.09% | 1.05% | 9.61% | 9.01% | Upgrade
|
| Free Cash Flow Margin | 2.35% | -2.05% | -13.00% | -12.54% | 6.64% | 1.85% | Upgrade
|
| EBITDA | 46,246 | 43,342 | 35,536 | 24,924 | 29,492 | 30,354 | Upgrade
|
| EBITDA Margin | - | 16.70% | 15.59% | 11.93% | 17.81% | 19.60% | Upgrade
|
| D&A For EBITDA | 22,123 | 20,099 | 17,888 | 19,409 | 10,954 | 10,425 | Upgrade
|
| EBIT | 24,123 | 23,243 | 17,648 | 5,515 | 18,538 | 19,929 | Upgrade
|
| EBIT Margin | - | 8.95% | 7.74% | 2.64% | 11.19% | 12.87% | Upgrade
|
| Effective Tax Rate | - | 27.89% | 33.88% | 52.20% | 28.46% | 25.47% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.